Tiragolumab
- Generic Name
- Tiragolumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT04665856
- Locations
- 🇨🇳
Cancer Center of Guangzhou Medical University, Guangzhou, China
🇨🇳Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou City, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT04665843
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States
🇺🇸MD Anderson Cancer Center; Oncology, Houston, Texas, United States
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT04632992
- Locations
- 🇺🇸
Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States
🇺🇸Ascension St. John Hospital, Detroit, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04619797
- Locations
- 🇧🇪
Vitaz, Sint Niklaas, Belgium
🇫🇷CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, France
🇯🇵The Cancer Institute Hospital of JFCR, Tokyo, Japan
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 83
- Registration Number
- NCT04584112
- Locations
- 🇺🇸
Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States
🇦🇺Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia
🇧🇷Hospital Sírio-Libanês, Sao Paulo, SP, Brazil
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 760
- Registration Number
- NCT04543617
- Locations
- 🇺🇸
MD Anderson Cancer Center; Oncology, Houston, Texas, United States
🇿🇦Limpopo Cancer Research Institute, Polokwane, South Africa
🇺🇸Compassionate Cancer Care Medical Group, Inc, Corona, California, United States
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 461
- Registration Number
- NCT04540211
- Locations
- 🇭🇰
Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong
🇹🇭Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand
🇨🇳Affiliated Hospital of Chengde Medical University, Chengde City, China
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 518
- Registration Number
- NCT04524871
- Locations
- 🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UCLA Center for East; West Medicine, Santa Monica, California, United States
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 829
- Registration Number
- NCT04513925
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States
🇺🇸Illinois Cancer Care, Peoria, Illinois, United States
🇺🇸New England Cancer Specialists, Brunswick, Maine, United States
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 148
- Registration Number
- NCT04486352
- Locations
- 🇺🇸
Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Englewood Health, Englewood, New Jersey, United States
🇺🇸Atlantic Health Systems/Morristown Medical Center, Morristown, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.